PH94B was developed from proprietary compounds called pherines. Administered as a nasal spray, Aloradine acts locally on peripheral nasal chemosensory receptors that trigger rapid activation of the limbic system areas of the brain associated with SAD. This mechanism of pharmacological action, the rapid onset of efficacy, and the excellent safety and tolerability profile shown in clinical trials make Aloradine an excellent product candidate for the acute intermittent and long-term treatment of individuals with SAD.
Congrats to all of us guys 😍
Aloradine we just can't wait for your approval!